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The -conotoxin Vc1.1 is a small disulfide-bonded peptide
currently in development as a treatment for neuropathic pain.
This study describes the synthesis, determination of the disul-
fide connectivity, and the determination of the three-dimen-
sional structure of Vc1.1 using NMR spectroscopy. Vc1.1 was
shown to inhibit nicotine-evoked membrane currents in iso-
lated bovine chromaffin cells in a concentration-dependent
manner and preferentially targets peripheral nicotinic acetyl-
choline receptor (nAChR) subtypes over central subtypes. Spe-
cifically, Vc1.1 is selective for 3-containing nAChR subtypes.
The three-dimensional structure of Vc1.1 comprises a small
-helix spanning residues Pro6 to Asp11 and is braced by the
I–III, II–IV disulfide connectivity seen in other-conotoxins. A
comparison of the structure of Vc1.1 with other -conotoxins,
taken together with nAChR selectivity data, suggests that the
conserved proline at position 6 is important for binding,
whereas a number of residues in the C-terminal portion of the
peptide contribute toward the selectivity. The structure
reported here should open new opportunities for further devel-
opment of Vc1.1 or analogues as analgesic agents.
Conotoxins are peptide toxins, ranging in size from 12 to 30
amino acids, isolated from the venom of snails from the Conus
genus (1). Members of this peptide family target a range of
membrane receptorswith bothhighpotency and selectivity and
as a consequence are useful as neuropharmacological probes
and have a range of potential pharmaceutical applications. The
-conotoxins are a subfamily of conotoxins that typically range
in size from 12 to 16 amino acids, which contain two disulfide
bonds in a I–III, II–IV connectivity and have an amidated C
terminus. The -conotoxins interact with both muscle and
neuronal nicotinic acetylcholine receptors (nAChRs),3 which
have been implicated in a range of disorders, including Alzhei-
mer disease, schizophrenia, depression, and small cell lung car-
cinoma, and they play a role in analgesia and addiction (2–5).
Selected -conotoxin examples are shown below in Fig. 1.
The -conotoxin Vc1.1 was first discovered using a PCR
screen of cDNAs from the venom ducts of Conus victoriae (6).
The cysteine spacingwithin the sequence of Vc1.1 suggests that
it is a member of the 4/7 subclass of -conotoxins, which
includes the extensively studied conotoxins MII, EpI and
PnIB, although the actual disulfide connectivity of Vc1.1 has
yet to be reported. In addition to an amidated C terminus,
which is common to all -conotoxins, Pro6 and Glu14 in
Vc1.1 are post-translationally modified to hydroxyproline
and -carboxyglutamate, respectively. The post-translation-
ally modified peptide, designated vc1a, was recently identi-
fied in the venom of C. victoriae using MS analysis (7).
SyntheticVc1.1, an antagonist of neuronal nAChRs in bovine
chromaffin cells, has been shown to alleviate neuropathic pain
in three rat models of human neuropathic pain and to acceler-
ate the functional recovery of injured neurons (8). As an anal-
gesic, Vc1.1 has been reported bemore active than-conotoxin
MVIIA, a conotoxin that has recently been approved as a treat-
ment for intractable pain (6). More recently, Vc1.1 was shown
to antagonize the nicotine-induced increase in axonal excitabil-
ity of unmyelinated C-fiber axons in isolated segments of
peripheral human nerves (9). Electrophysiological and immu-
nohistochemical data indicate the functional expression of
nAChRs composed of 3, 5, and 4 but not 4, 2, or 7
subunits in axons of unmyelinated C fibers (9, 10). Blockade of
nAChRs on unmyelinated peripheral nerve fibers may have an
analgesic effect on unmyelinated sympathetic and/or sensory
axons. Interestingly, synthetic vc1a was reported to not inhibit
the neuronal-type nicotinic response in chromaffin cells and
was inactive in two rat neuropathic pain assays (7). Vc1.1 is now
under development as a treatment for neuropathic pain (5, 11)
but neither a specific receptor target nor the structure has been
reported.
Herein, we report the three-dimensional structure of Vc1.1
in solution as determined by NMR spectroscopy and explicitly
determine the disulfide connectivity via chemical reduction
and MS analysis. In addition, we show that Vc1.1 selectively
antagonizes peripherally expressed nAChRs subtypes over
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those typically expressed in the central nervous system. These
findings provide an insight into the potentialmodes of action of
this analgesic peptide. We also examined the structure and
activity of two derivatives of Vc1.1, vc1a and [P6O]-Vc1.1,
which contain the post-translationally modified residues
hydroxyproline and-carboxyglutamic acid and compare them
to our findings for Vc1.1.
EXPERIMENTAL PROCEDURES
Peptide Synthesis and Oxidative Folding—Vc1.1, vc1a, and
[P6O]-Vc1.1wereassembledon4-methylbenzhydrylamineamide
resin (Auspep) by manual solid-phase peptide synthesis using the
in situ neutralization/O-benzotriazole-N,N,N,N-tetramethylu-
ronium hexafluorophosphate protocol for t-butoxycarbonyl
chemistry (12). Cleavage of the peptide from the resin was
achieved using HF with p-cresol and p-thiocresol as scavengers
(9:0.5:0.5 (v/v) HF:p-cresol:p-thiocresol). The reaction was
allowed to proceed at 5 to 0 °C for 1.5 h. The HF was then
removed under vacuum, and the peptide was precipitated with
ether, filtered, dissolved in 50% acetonitrile containing 0.05%
trifluoroacetic acid, and lyophilized. The crude peptides were
purified by RP-HPLC on a Phenomenex C18 column using a
gradient of 0–80%B (Buffer A: H2O/0.05% trifluoroacetic acid;
Buffer B: 90%CH3CN/10%H2O/0.045% trifluoroacetic acid) in
80 min, and the eluant was monitored at 230 nm. These condi-
tionswere used in subsequent purification steps. Analytical RP-
HPLC and ES-MS confirmed the purity and molecular mass of
the synthesized peptides. The linear peptides were oxidized by
dissolving in 0.1 MNH4HCO3 (pH 8.2) at a concentration of 0.3
mg/ml and stirring overnight at room temperature. The oxi-
dized peptides were then purified by RP-HPLC, and themolec-
ular weight was confirmed by ES-MS.
Determination of Disulfide Connectivity—Peptide (50 g)
was dissolved in 50l of 0.2 M sodiumcitrate (pH3.0), and 50l
of 20 mM tris-carboxyethylphosphine in citrate buffer was
added. The reaction mixture was incubated at 37 °C for 5 min
before injection onto the RP-HPLC. The partially reduced pep-
tide was collected, and an equal volume of 20 mM N-ethylma-
leimide in citrate buffer was added immediately. The reaction
mixture was then incubated at 60 °C for 1 h, and the resulting
product was isolated by RP-HPLC and lyophilized. The peptide
was then redissolved in citrate buffer and fully reduced with an
excess of tris-carboxyethylphosphine, resulting in a peptide
with two free cysteines and two alkylated cysteines. This pep-
tide was then analyzed by MS/MS sequencing to identify the
location of the alkylated cysteines in the sequence.
NMR Spectroscopy—NMR data for Vc1.1, vc1a, and [P6O]-
Vc1.1 were recorded on samples dissolved in 90% H2O/10%
D2O at pH 3.5. Bruker ARX 500- and 600-MHz spectrometers
were used in the acquisition of data. 2D NMR experiments
included DQF-COSY, E-COSY, TOCSY, and NOESY, with all
spectra recorded at 280 K. A series of 1D and TOCSY spectra
acquired immediately following dissolution of fully protonated
Vc1.1 in D2O were used in the determination of slow exchang-
ing NH protons. All spectra were analyzed on Silicon Graphics
Indigo workstations using XWINNMR1.3 (Bruker) and Sparky
software. Chemical shifts were referenced to 2,2-dimethyl-2-
silapentane 5-sulfonate at 0 ppm.
Structure Calculations on Vc1.1—Distance information for
Vc1.1 was obtained from a NOESY spectrum with a mixing
time of 200 ms at 280 K. Peak heights were used to determine
distance restraints. Backbone dihedral restraints were deter-
mined from 3JHN-H coupling constants obtained from line-
shape analysis of the anti-phase cross-signal splitting in a high
digital resolution 2D DQF-COSY spectrum or from a 1D 1H
NMR spectrum. The  angle was restrained to 120  30° for
3JHN-H  8 Hz and 60  30° for 3JHN-H  5.8 Hz. Intra-
residue NOE and 3JH-H coupling patterns were used in
assigning 1 angle restraints of some side chains. There were
also 12 restraints included for 6 hydrogen bonds identified from
D2O exchange data and preliminary structures.
Initial structures were generated using Dyana software (13),
and the final structure calculationswere performedusing a sim-
ulated annealing protocol with CNS (14). This protocol
involves a high temperature phase comprising 4000 steps of
0.015 ps of torsion angle dynamics, a cooling phase with 4000
steps of 0.015 ps of torsion angle dynamics during which the
temperature is lowered to 0 K, and finally an energy minimiza-
tion phase comprising 500 steps of Powell minimization. The
resultant structures were subjected to further molecular
dynamics and energy minimization in a water shell (15). The
refinement in explicit water involved the following steps. First,
heating to 500 K via steps of 100 K, each comprising 50 steps of
0.005 ps of Cartesian dynamics. Second, 2500 steps of 0.005 ps
of Cartesian dynamics at 500 K before a cooling phase where
the temperature is lowered in steps of 100 K, each comprising
2500 steps of 0.005 ps of Cartesian dynamics. Finally, the struc-
tures were minimized with 2000 steps of Powell minimization.
Fifty structures were calculated, and the 20 with the lowest
overall energies were retained for analysis. Structures were
visualized using the programMOLMOL (16) and analyzedwith
PROMOTIF (17) and PROCHECK_NMR (18).
Electrophysiological Recordings fromnAChRs inBovineAdre-
nal Chromaffin Cells and Exogenously Expressed in Xenopus
Oocytes—Chromaffin cells were prepared from bovine adrenal
glands and maintained on glass coverslips in 24-well plates
(Nunc) as previously described (19). Electrodes (GF150F-7.5,
HarvardApparatus Ltd., Edenbridge, UK)were pulled, fire-pol-
ished, and had resistances of 2–3Mwhen filled with intracel-
lular solution (in mM: 140 CsCl, 2 CaCl2, 11 EGTA, 2 MgATP,
10 HEPES-KOH, pH 7.2). Agonists were diluted in bath solu-
tion (in mM: 140 NaCl, 3 KCl, 1.2MgCl2, 2.5 CaCl2, 7.7 glucose,
10 HEPES-NaOH, pH 7.35) and were applied to cells by brief
(10 ms) pressure ejection (15 p.s.i., Picospritzer II, General
Valve, Fairfield, NJ) from an extracellular pipette positioned
50 m from the cell to evoke maximal responses to agonists
(20). Conotoxins were bath applied and co-applied with the
agonist in the extracellular pipette. Membrane currents evoked
by agonist application were amplified and low pass filtered (10
kHz) using an MultiClamp 700B patch clamp amplifier (Axon
Instruments Inc., Union City, CA), and voltage steps were gen-
erated from a PC Pentium computer using pCLAMP 9.2 soft-
ware and a Digidata 1322A interface (Axon Instruments Inc.).
All experiments were carried out at room temperature (22 °C).
RNA preparation, oocyte preparation, and expression of
nAChR subunits in Xenopus oocytes were performed as
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described previously (21). Briefly, plasmids with cDNA encod-
ing the rat 1–7, 1–4, , and  nAChR subunits were pro-
vided by J. Patrick (Baylor College of Medicine, Houston, TX)
and subcloned into the oocyte expression vector pNKS2. All
oocytes were injected with 5 ng of cRNA, except the 5- and
6-containing nAChRs in which 15–20 ng of each subunit was
injected to aid expression and then kept at 18 °C inND96 buffer
(96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM
HEPES, at pH 7.4) supplemented with 50 mg/liter gentamycin
and 5 mM pyruvic acid 2–5 days before recording.
Membrane currents were recorded from Xenopus oocytes
using an automatedwork stationwith eight channels in parallel,
including drug delivery and on-line analysis (OpusXpressTM
6000A workstation, Axon Instruments Inc.). Both the voltage-
recording and current-injecting electrodes were pulled from
borosilicate glass (GC150T-15, Harvard Apparatus Ltd.) and
had resistances of 0.3–1.5 M when filled with 3 M KCl. All
recordings were conducted at room temperature (20–23 °C)
using a bath solution of ND96 as described above. HEPES (pKa
7.48) was replaced by MES (pKa 6.1) as the buffer in the bath
solution for experiments carried out at pH 6.0. During record-
ings, the oocytes were perfused continuously at a rate of 1.5
ml/min, with 250-s incubation times for the conotoxin. Acetyl-
choline (100 M) was applied for 2 s at 5 ml/min, with 600-s
washout periods between applications. Cells were voltage-
clamped at a holding potential of80 mV. Data were sampled
at 500 Hz and filtered at 200 Hz. Peak current amplitude was
measured before and following incubation of the toxin.
Statistics—All data represent arithmetic means  S.E. Con-
centration-response curves for antagonists were fitted by
unweighted non-linear regression to the logistic equation,
Ex	 EmaxX
n/Xn
 IC50
n	 (Eq. 1)
where Ex is the response, X is the antagonist concentration,
Emax is the maximal response, n is the slope factor, and IC50 is
the concentration of antagonist that gives 50% inhibition of the
agonist response. Computation was done using SigmaPlot 8.0
(Jandel Corp.).
The rate of onset and recovery fromblock during toxinwash-
out were obtained from single exponential fits to the data using
SigmaPlot 8.0. The Kd for the toxin was then calculated using
Equation 2,
Kd 	 koff/kon (Eq. 2)
where koff 
 1/off (s1) and kon 
 (1/on  koff)/[toxin]. The
mechanisms of competitive antagonism were evaluated by
means of the Schild regression (22),
logx 1		 log Ki npAx (Eq. 3)
where pAx is the negative logarithm of the concentration of the
inhibitor, x is the shift of the concentration-response curve
(dose ratio) caused by its presence, Ki is the dissociation con-
stant of the inhibitor, and n is the slope factor. The regression
line fitted to the data intersects the abscissa at a point corre-
FIGURE 1. Sequences of selected-conotoxins, including Vc1.1. Standard
one letter codes are used,withO representing hydroxyproline, a-carboxy-
glutamic acid, and Ys a sulfonated tyrosine. An asterisk indicates an amidated
C terminus, which is a commonpost-translationalmodification of-conotox-
ins. The common disulfide framework of I–III, II–IV is indicated at the top, and
the conserved cysteines are shaded. The residues between Cys-II and Cys-III
and Cys-III and Cys-IV are commonly referred to as loops 1 and 2, respectively,
and are indicated by the black bars at the bottom. The number of residues in
each of these loops is used to further classify the -conotoxins. For example,
Vc1.1 is classified as a 4/7 -conotoxin, whereas ImI is a 4/3 -conotoxin. The
selectivity for nAChR subtypes of each conotoxin is shown on the right. Resi-
dues important for potency and/or selectivity are highlighted by a box. Ref-
erences to the various conotoxins are as follows: MII (44), EpI (39), PnIA (46),
PnIB (46), GIC (47), GID (48), and ImI (49).
FIGURE 2. HPLC profiles for the oxidation of Vc1.1 (a), vc1a (b), and [P6O]-Vc1.1 (c). In each case, the top trace shows an RP-HPLC chromatogram of the
reducedpeptide. Thebottom trace shows anRP-HPLC chromatogramof theoxidationmixture after incubation in 0.1MNH4HCO3 for 24h at room temperature.
The disulfide connectivity of the major product for each peptide was confirmed as I–III, II–IV by partial reduction and MS/MS sequencing.
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sponding to pA2, which in the case of n 
 1 corresponds to Ki
(22).
RESULTS
Peptide Synthesis and Oxidative Folding—The sequence of
Vc1.1 is shown in Fig. 1. The post-translationally modified
derivative of Vc1.1, vc1a, which is found in the venom, contains
a hydroxyproline in position 6 and a -carboxyglutamic acid in
position 14. To further define the roles of these modified resi-
dues a third peptide, [P6O]-Vc1.1, was made that contained a
hydroxyproline in position 6 but retained the unmodified glu-
tamic acid at position 14. Vc1.1, vc1a, and [P6O]-Vc1.1 were
synthesized using t-butoxycarbonyl/in situ neutralization
chemistry on 4-methylbenzhydrylamine amide resin. The over-
all yield of reduced peptides based on the initial starting resin
was 30%. The oxidation profile of the peptides in 0.1 M
NH4HCO3 buffer are shown in Fig. 2. All three peptides, Vc1.1,
vc1a, and [P6O-Vc1.1, formed almost exclusively a single iso-
mer with a monoisotopic molecular weights of 1809.7, 1866.6,
and 1821.6, respectively, determined by ES-MS.
Disulfide Mapping of Vc1.1—Vc1.1, vc1a, and [P6O]-Vc1.1
were partially reduced by incubating with tris-carboxyeth-
ylphosphine in citrate buffer at low pH. The reaction mixture
was purified by RP-HPLC, and the one-disulfide species was
alkylated with N-ethylmaleimide. The alkylated peptide was
then fully reduced and analyzed by MS/MS. For all three pep-
tides the MS/MS data clearly showed that C2 and C8 had been
alkylated with N-ethylmaleimide. Fragmentation patterns from
both ends of the peptide chain were observed and fully supported
the proposed alkylation pattern. Therefore, it was concluded that
the disulfide connectivity of Vc1.1, vc1a, and [P6O]-Vc1.1 was C2
toC8 andC3 toC16. This is consistent with the I–III, II–IV disul-
fide bonding pattern seen in other -conotoxins.
NMR Analysis—NH-NHi1, H-NHi1, and H-NHi1
connectivities obtained from the NOESY spectrum were used
in the sequential assignment of the individual spin systems
determined from the TOCSY spectrum. Sequential
H-NHi1 connectivities in all three peptides were observed
for the entire peptide chain except at Pro6 and Pro13.
H-Hi1 connectivities were utilized in the assignment of
these proline residues and incidentally confirmed that the
X-Pro bonds were in the trans configuration. Analysis of
chemical shift data indicated that residues Cys2–Ser4, P/O6–
Asp11, and Pro13–Cys16 all have a negative secondary shifts
(Fig. 3a), indicating helical character. This is further sup-
ported by the small 3JN coupling constants observed for
Vc1.1 and the slow D2O exchange of the amide resonances
for many of these residues (Fig. 3c). This predominance of
helical character is characteristic of other -conotoxin
structures reported to date (4). Fig. 3 (a and b) illustrates the
high degree of structural similarity between the three mole-
cules. The secondary shifts are almost identical except for where
there is a change in residue type at positions 6 and/or 14. This
similarity in structure is reinforced by the fact the secondary shift
for [P6O]-Vc1.1 matches vc1a at position 6 (as both share a
hydroxyproline at this position) andmatches Vc1.1 at position 14
(both Glu). A comparison of the chemical shift differences
between the H protons, shown in Fig. 3b, suggests that the side-
chain orientations in each molecule are also very similar. There-
fore, any differences in biological activity between the three pep-
tides is most likely due to changes in the nature of the side chains
rather than structural perturbations.
FIGURE 3. A comparison summary of the NMR data for Vc1.1, vc1a, and
[P6O]-Vc1.1. a, secondary shift values for Vc1.1 (filled circles), vc1a (filled
squares), and [P6O]-Vc1.1 (open triangles). The values for each peptide are
almost identical indicating that the three-dimensional structures are very
similar. b, a comparison of the chemical shift difference between H protons
for Vc1.1 (black), vc1a (white), and [P6O]-Vc1.1 (gray) indicating that the ori-
entations of the side chains in each peptide are comparable. c, summary of
coupling constants, chemical shift index, amide exchange and sequential-,
medium-, and long-range NOE connectivities for Vc1.1. Solid bars represent
sequential NOE connectivities observed in a 200-ms NOESY spectrum from a
500-MHz spectrometer at 280 K. The height of the bar represents the strength
of the NOE cross-peak, classified as either strong, medium, or weak. 3JNH-H
coupling constants  8 Hz (120°) are represented as upward arrows, and
coupling constants 5 Hz (60°) are represented as downward arrows. Filled
circles indicate slow exchanging amide protons still present 30 min after dis-
solution in 2H2O at 298 K. Chemical shift indices (50) were derived from H
chemical shifts of Vc1.1. An index of1 or1 indicates a shift deviation from
the random coil value of0.1 ppm upfield or downfield, respectively.
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Structure Determination of Vc1.1—The solution structure of
Vc1.1 was determined by simulated annealing using experi-
mental distance restraints based on NOESY cross-peaks and
dihedral angle restraints based on coupling constants. The
restraints comprised 21 dihedral angle and 92 distance
restraints, which included 59 sequential, 28medium range, and
5 long range NOEs. Fifty structures were calculated, and the 20
lowest energy structures were chosen as representatives of the
solution structure of Vc1.1 as shown in Fig. 4a. A summary of
the energetic and geometric statistics for the family of struc-
tures is given in Table 1. The structures are in excellent agree-
mentwith the experimental data, showing no distance violation
0.2 Å and no dihedral angle violation2°.
In general, the fold of Vc1.1, shown in Fig. 4, is consistent
with that seen in other -conotoxins. The main secondary
structural element is an -helix spanning residues Pro6 to
Asp11. In addition, PROMOTIF (17) recognizes a type I -turn
at the N terminus of the peptide for residues Cys2 to Ser4. In 7
out of the 20 structures in the ensemble the 2–8 disulfide of
Vc1.1 is defined as a right-hand hook conformation (2ve, 3
ve, 2 ve), and in the remaining structures (13 of 20) the
conformation is not formally classified by PROMOTIF (2ve,
3ve, 2ve). In all 20 structures
the 3–16 disulfide bond is in a left-
hand spiral conformation. A com-
parison of the 2–8 disulfide bond in
Vc1.1 with the crystal structures of
[A10L,D14K]-PnIA and ImI in
complex with the acetylcholine-
binding protein (AChBP) (23)
shows that the 2–8 disulfide of both
peptides is similar to that of the 2–8
disulfide of Vc1.1 (i.e. 2 ve, 3
ve, and 2 ve).
Potency of -Conotoxin Vc1.1 at
Native nAChRs—The functional activity of Vc1.1 was investi-
gated via its effects on nicotine-evoked membrane currents in
dissociated bovine chromaffin cells. Bath application of Vc1.1
reversibly inhibited nicotine (100 M)-evoked depolarizing
membrane currents in chromaffin cells voltage clamped at
100mV (Fig. 5a). Highmicromolar concentrations (10M)
of the toxin almost completely blocked the nicotine-evoked
current in chromaffin cells, which recovered completely upon
washout (Fig. 5b). Fig. 5c shows the concentration-response
relationship obtained for inhibition of nicotine-evoked current
amplitude by bath-applied Vc1.1. The curve fitted according to
Equation 1 gave a half-maximal inhibitory concentration (IC50)
of 1.54  0.14 M and slope factor (Hill coefficient) of 1.64 
0.22 (n
 6). The time courses of onset of inhibition of nicotine-
evoked current obtained in the presence of toxin and the recov-
ery from block during toxin washout were fitted by single expo-
nential functions. On- and off-rates of nAChR inhibition and
estimates of potency (Kd) were obtained following application
and washout of Vc1.1. Vc1.1 (10 M) exhibited rapid onset of
block (kon
 1.3 0.1 103 M1 s1) and a maximum inhibi-
tion to 11 2% (n
 6) of control. Recovery from block to 81
4% (n 
 6) of control was obtained after 10 min washout (Fig.
5b) and was associated with a dissociation rate constant, koff

4.4 0.1 103 M1 s1. Therefore, using Equation 2, a Kd of
3.4 106 M was calculated.
Fig. 6a shows whole cell membrane currents evoked by focal
application of 100 M nicotine to the chromaffin cell held at
different membrane potentials. Whole cell I–V relations
obtained for peak nicotine-evoked currents obtained in the
absence and presence of 1 M and 2.5 M Vc1.1 are shown in
Fig. 6b. Vc1.1 reversibly inhibited nicotine-evoked current
amplitude by 53% and 77% (n
 6) at all membrane poten-
tials in the presence of 1 M and 2.5 M Vc1.1, respectively,
indicating that the block of nAChRs by Vc1.1 was voltage-
independent.
Competitive antagonism of nAChRs in chromaffin cells by
Vc1.1 was evaluated from nicotine concentration-response
relations determined in the absence and presence of various
concentrations of Vc1.1. A rightward shift without noticeable
depression of the concentration-response curve was observed
for nicotine-induced currents in the presence of 0.5 M, 1 M,
and 2.5 M Vc1.1 (Fig. 6c). Schild plots constructed from shifts
(dose ratios) of nicotine concentration-response curves in the
absence and presence of Vc1.1 revealed pA2 values of 6.33 (Fig.
6d). The slope of the Schild regression did not significantly
FIGURE 4. The three-dimensional structure of Vc1.1. a, stereoview of an ensemble of 20 low energy struc-
tures of Vc1.1 superimposedover all thebackboneN, C, andCatoms. Every fifth residue, and the cysteines are
numbered. b, ribbon representation of the average structure of Vc1.1 showing the helical region between
residues Pro6 and Asp11. Disulfide bonds are shown in yellow in ball-and-stick representation, and the N and C
termini are marked.
TABLE 1
Energy and structural statistics for the family of 20 structures
representing the solution structures of Vc1.1
Energies (kcal/mol)
Overall 623 15
Bond 2.52 0.34
Angle 15.4 2.3
Improper 3.57 0.70
van der Waals 27.7 4.3
NOE 3.55 1.22
cDih 0.992 0.267
Dihedral 54.5 6.2
Electrostatic 676 20
R.m.s.d.
Bond (Å) 0.003 0.0002
Angle (degrees) 0.49 0.04
Improper (degrees) 0.43 0.04
NOE 0.025 0.004
cDih 0.89 0.12
Pairwise r.m.s.d. 0.32 0.13
Backbone/heavy (Å) 1.32 0.37
Experimental data
Distance restraints 92
Dihedral restraints 21
NOE violations exceeding 0.20 Å 0
cDih violations exceeding 2.0° 0
Ramachandran
Most favored (%) 91.7
Additionally allowed (%) 8.3
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differ fromunity (0.99), because the confidence interval of the
estimate of the slope included 1 at the 5% significance level.
Selectivity of -CTX Vc1.1 Inhibition of Recombinant nAChR
Subtypes—Vc1.1 inhibition of ACh-induced currents was
examined in Xenopus oocytes expressing various nAChRs sub-
unit combinations. The ACh-evoked response was assessed
every 10 min, and the toxin was bath-applied 4 min prior to
co-application of the agonist plus toxin. Vc1.1 (10 M) failed to
inhibit ACh-evoked currents mediated by either the central
nAChR subtypes, 42 and 44, or the skeletal muscle
nAChR subtype, 11 (n
 7–12) (Fig. 7 and Table 2). Sim-
ilarly, 10 M Vc1.1 inhibited only 14  2% of the ACh-evoked
currentmediated by the homopentameric neuronal nAChR,7
(n 
 11) (Fig. 7 and Table 2). However, 10 M Vc1.1 inhibited
the peripheral nAChR subtypes 32 and 34 to a similar
extent, 58  7% (n 
 8) and 56  7% (n 
 12) of control,
respectively. A similar potency was observed upon addition of
the5 subunit to the nAChR combination,352 (n
 7), but
Vc1.1 exhibited5-fold lower potency to inhibit 354 (n

5). Bath application of Vc1.1 at concentrations of 100 nM
did not antagonize ACh-evoked currents nor elicit a detect-
able response alone (i.e.50 nA) for 3-containing nAChRs.
In a series of experiments, responses to ACh (100 M) were
measured before and after incubation with toxin at pH 7.4
and 6.0. Although extracellular acidification has been shown
to inhibit neuronal nAChRs (24, 25), at pH 6.0, 1 M Vc1.1
inhibited 34 by 44 0.1% (n
 4), which was significantly
more than that obtained at pH 7.4 (19  0.1% inhibition)
(data not shown).
The post-translationally modified peptides vc1a and [P6O]-
Vc1.1 were also examined in Xenopus oocytes, under the same
conditions as Vc1.1. Application of 10 M vc1a or [P6O]-Vc1.1
failed to inhibit ACh-evoked currentsmediated by 11, 7,
44, 42, 34, and 32 nAChRs subunit combinations
expressed in oocytes (n
 4–9). Higher concentrations of vc1a
and [P6O]-Vc1.1 (30 M) were also inactive on the 32 and
34 subtypes (n
 2) (data not shown).
FIGURE 6. Inhibition of nAChRs in bovine chromaffin cells by Vc1.1. a,
superimposed nicotine-evoked currents elicited by brief pulses (10 ms, as
indicated by the triangle) of 100 M nicotine from isolated chromaffin
cells, voltage-clamped at membrane potentials from 100 to 40 mV in
20-mV increments. b, whole cell current-voltage relations obtained for
peak current density (pA/picofarad) in the absence (control, open circles)
and presence of 1 M (filled circles) and 2.5 M (filled squares) Vc1.1 bath
applied. c, concentration-response relations of nicotine-evoked mem-
brane currents from isolated chromaffin cells in the absence (control, open
circles) and presence of 1M (filled circles) and 2.5M (filled squares) Vc1.1.
Curves were fitted according to Equation 1. Curve shifts (dose ratios)
caused by 0.5, 1, and 2.5 M Vc1.1 were 2.1 1.2, 2.9 1.5, and 6.4 1.6,
respectively. Data are means  S.E., n 
 4–6 from three different prepa-
rations. d, Schild plot of dose ratios were calculated from curve shifts in the
presence of a given concentration of the antagonist by fitting data points
to Equation 1. The line fitted to the data has a slope of 0.99  0.11 (S.E.),
which does not significantly differ from unity and intersects the dotted line
at 6.33 (pA2 value, Equation 3).
FIGURE5.ConcentrationdependenceofVc1.1 inhibitionofnicotine-evoked currents inbovineadrenal chromaffin cells.a, superimposednicotine (100
M)-evoked current traces recorded from isolated bovine chromaffin cells voltage-clamped at100 mV in the absence and presence of different concentra-
tions of Vc1.1 (as stated). b, normalized peak current amplitude as a function of time showing the onset (open circles) and recovery from block by Vc1.1 upon
washout (filled circles). Current responseswere evoked at 60-s intervals tominimize receptor desensitization. The toxinwas applied as indicated. The onset and
recovery fromblockwere obtained from curve fits according to Equation 2 (n
 4). c, concentration-response relationship for the inhibition of nicotine evoked
membrane currents from isolated bovine chromaffin cells by increasing concentrations of Vc1.1. Curve were fitted according to Equation 1.
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DISCUSSION
In this study we have synthesized the -conotoxin Vc1.1,
determined its disulfide connectivity and three-dimensional
structure, and identified its selectivity and potency for nAChR
subtypes. The peptide was found to fold efficiently into one
predominant isomer, which was subsequently determined to
have a I–III, II–IV disulfide connectivity common to all
-conotoxins. These two disulfide bonds are the driving force
for establishing the correct overall fold of the molecule and
provide structural rigidity. Vc1.1 was shown to inhibit the nic-
otine-induced membrane current in bovine chromaffin cells in
a concentration-dependent manner with a potency consistent
with the observed inhibition of release of catecholamines (6).
Moreover, Vc1.1 exhibited selectivity for 3-containing
nAChRs, with similar potency for 32 and 34 nAChR sub-
unit combinations. The potency of 32 was not altered by the
addition of the 5 subunit, whereas the addition of the 5 sub-
unit to 34 reduced the potency 5-fold. In contrast, Vc1.1
exhibited two-site displacement of [3H]epibatidine from chro-
maffin cell membranes (Ki values of 2.3 nM and 3.7 M), which
suggests that Vc1.1 is a specific competitive inhibitor of one of
the nAChR subtypes (6). Overall, Vc1.1 preferentially targets
peripheral over central nAChR subtypes, but the difference
between the radioligand binding and electrophysiological
assays remains unresolved. The
modified analogues vc1a and [P6O]-
Vc1.1 did not inhibit ACh-evoked
currents mediated by any of the
nAChR subtypes expressed inXeno-
pus oocytes. The lack of activity of
vc1a on neuronal nAChR subtypes
is consistent with that reported pre-
viously in bovine chromaffin cells
and rat models of neuropathic pain
(26).
The three-dimensional structure
of Vc1.1 reveals that it is a compact
molecule dominated by a helical
region over residues Pro6 to Asp11.
The r.m.s.d. for the backbone atoms
in the family of structures is 0.32 
0.13 Å, which indicates that the
structure of the molecule is well
defined. Overall, the three-dimen-
sional fold of Vc1.1 is similar to
those found for other 4/7 -cono-
toxins. For example, a comparison of Vc1.1 with EpI (27), MII
(28, 29), and PnIB (30) shows that the backbones overlay with
r.m.s.d.s of only 0.47, 0.98, and 0.39 Å, respectively. A compar-
ison of the NMR chemical shift data for vc1a and [P6O]-Vc1.1
with that for Vc1.1 showed that these two post-translationally
modified analogues were structurally analogous to Vc1.1, and,
therefore, the lack of biological activity of these two peptides
was likely due to the side-chain modifications and not a struc-
tural perturbation. Notably, the surface properties of Vc1.1,
shown in Fig. 8a, differ significantly from many other 4/7
-conotoxins. This class of conotoxins typically has a patch of
hydrophobic residues on one face that is believed to play a role
in receptor binding and determining subtype specificity. It is
clear from Fig. 8 that Vc1.1 has fewer hydrophobic residues on
its surface than the-conotoxins EpI (Fig. 8b) andMII (Fig. 8c),
which are selective for the 34 and 32 nAChR subtypes,
respectively.
Vc1.1 shares a number of common residues, apart from the
conserved cysteines, with other -conotoxins. The proline in
position 6 is present in all -conotoxins except for the recently
discovered ImII, which acts at a different site on the nAChR
(31). This proline residue has both a structural role and is also
thought to contribute a key hydrophobic binding interaction
with the  subunit of the nAChR (32). Recently, three crystal
structures of -conotoxins in complex with the AChBP have
been published (23, 33, 34). All three structures reveal that loop
1 of the -conotoxins, which includes Pro6, is a key contributor
to receptor binding. In the post-translationally modified ana-
logue of Vc1.1, vc1a, Pro6 is converted to a hydroxyproline and
Glu14 is converted to a -carboxyglutamic acid (7). This modified
peptide does not inhibit the nicotine-induced response in chro-
maffincells (7), andweshowhere that this isdue toa lossof activity
at the 32 and 34 nAChR subtypes. One or both of these
post-translational modifications must result in the loss of activity
seen for vc1a, and it seems likely that the hydroxyproline is the
major cause, because hydroxylation of this residue would dis-
FIGURE 7. Selectivity of Vc1.1 inhibition of nAChR subunit combinations expressed in Xenopus oocytes.
a, Vc1.1 (10M) inhibits 58 8% (n
 7) of the ACh-evoked current amplitudemediated by 32 nAChRs but
fails to inhibit42 nAChRs expressed in oocytes. b, concentration-response curve of Vc1.1 inhibition of32
receptors gave an IC50 of 7.3 M (filled diamonds, nH 
 1.7) and 4.2 M (filled squares, nH 
 1.3) for 34
receptors but only to a maximum of 71% inhibition. Addition of the 5 subunit for 352 receptors (open
diamonds) did not change the IC50 (7.2 M, nH
 1.3) but reduced the potency of Vc1.1 for 354 receptors
(open squares) by 5-fold. In contrast, Vc1.1 was 100-fold less potent on other nAChR subtypes: 7 (open
circles), 11 (filled circles), 42 (filled triangles), and 44 (open triangles). Each data point represents the
average of 4–7 oocytes. Error bars areS.E.
TABLE 2
 -Conotoxin Vc1.1 inhibition of recombinant nAChR subunit
combinations expressed in Xenopus oocytes
nAChR subtype IC50 n Hill slope Maximuminhibitiona
M %
352 7.2 0.2 7 1.3 0.3 94
32 7.3 0.7 12 1.7 0.2 90
34 4.2 1.6 12 1.3 0.6 70
354, 42, 44,
7, and 
30 5–12 20
aMaximal inhibition was estimated from curves fitted to the data obtained at a
maximum concentration of 30 M.
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rupt the conserved hydrophobic interactions with the nAChR.
The key role of these interactionswas confirmed by synthesis of
[P6O]-Vc1.1, which has a hydroxyproline at position 6 but
retains the glutamic acid at position 14. This peptide was also
inactive on the nAChR and hence confirmed the key role of
Pro6 in the interaction of the conotoxin with the receptor,
because presumably the presence of the hydroxyl group dis-
rupts the hydrophobic interactions.
Fig. 9a shows the structure of Vc1.1 superimposed over the
backbone of [A10L,D14K]-PnIA (backbone r.m.s.d.
 0.25 Å).
The latter structure is derived from the crystal structure of
[A10L,D14K]-PnIA, a 4/7 -conotoxin, bound to the AChBP
fromAplysia californica (23). TheAChBP is a homologue of the
extracellular ligand binding domain
of the nAChR. As can be seen in Fig.
9b the highly conserved Pro6 has
hydrophobic interactions with both
Trp145 and Tyr53, whereas Glu14 is
solvent-exposed and appears to be
less important for the binding of the
conotoxin to the receptor but may
influence the selectivity of Vc1.1.
This result is also consistent with a
mutagenesis study on PnIB, which
showed that substituting the proline
at position 6 with a hydroxyproline
resulted in a reduction in activity of
15-fold at the 7 nAChR subtype
(35).
In -conotoxins it is generally
found that the selectivity for 32
and 34 over the 7 nAChR sub-
type expressed in Xenopus oocytes
is influenced by the length of the
side chain of the hydrophobic resi-
due at position 10, with longer
extended aliphatic side chains tend-
ing to favor 7 selectivity (35–38).
Vc1.1 has a tyrosine, relative to Val,
Leu, Met, Ala, or Gly in other
-conotoxins, at position 10 and is
selective for the 32 over the 7
nAChR subtype. The structure of
Vc1.1 described here shows that the
hydroxyl group of this tyrosine is
surface-exposed, and therefore the
combination of this hydroxyl group
and the bulkier aromatic ring may
disfavor interaction of Vc1.1 with
the 7 nAChR subtype (Fig. 8a).
Vc1.1 has an identical sequence
to EpI for the first nine residues, i.e.
GCCSDPRCN but differs in five of
the seven C-terminal residues. The
sequence similarity is reflected in
the surface characteristics of the
two peptides shown in Fig. 8. The
surfaces of the N-terminal portion
of Vc1.1 (Fig. 8a) and EpI (Fig. 8b) exhibit a very similar distri-
bution of hydrophobic, polar, and charged residues. EpI is a
potent inhibitor of nAChRs in both bovine chromaffin cells and
rat parasympathetic neurons that are rich in 34 and 32
subtypes, respectively (39). However, EpI inhibits rat 7
nAChR subtypes expressed in oocytes and has little effect on
oocyte-expressed 32 and 34 subtypes (38). Although
Vc1.1 shows negligible activity at the 7 nAChR subtypes
expressed in oocytes, it is active in inhibiting nicotine-induced
membrane currents and catecholamine release from bovine
chromaffin cells and is active on 32 and 34 nAChR sub-
types expressed in oocytes. This suggests that the differences in
activity for EpI and Vc1.1 at the rat 7 nAChR subtype
FIGURE 8. Surface features of the -conotoxins. a, Vc1.1; b, EpI (PDB ID 1AOM); and c, MII (PDB ID 1MII). The
surface image on the right for each conotoxin is rotated 90° around the horizontal axiswith respect to the left
image. Hydrophobic residues (Ala, Ile, Leu, Met, Pro, and Val) are shown in green, polar residues (Asn, His, Ser,
Thr, and Tyr) arewhite, positive residues (Arg) are blue, negative residues (Asp and Glu) are red, glycine is light
blue, and cystines are yellow. The histidine is assumed to be unprotonated at physiological pH. The structure of
EpI is of the non-sulfonated tyrosine analogue.
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expressed in oocytes must be dependent upon residues 10–15.
Of these residues, Tyr10 (Vc1.1) versus Met10 (EpI) would
appear to be themajor cause of this difference, because amethi-
onine in position 10 has been shown in PnIA to strongly favor
interaction with the 7 subtype (35). In addition, mutation of
Tyr15 to alanine in PnIB reduces activity at the 7 nAChR sub-
type by 2-fold. Vc1.1 has an isoleucine in position 15 rather
than the sulfated tyrosine present in EpI, and this may also
contribute to the lack of activity of Vc1.1 on the 7 subtype.
Recently, the 4/3 -conotoxin ImI has been shown to be a
potent inhibitor of the 32 nAChR subtype when it was pre-
viously believed to be only selective for the homomeric 7
receptor (34, 40). ImI is identical in sequence to Vc1.1 (and EpI)
from residues 1 through 8, and therefore the activity of ImI on
32 receptors is consistent with the activity profiles of Vc1.1
and EpI. Again, the difference in the second loops of ImI and
Vc1.1 must explain the why ImI is active on the 7 nAChR
subtype and Vc1.1 is not. ImI has only a short second loop
(three residues), and it has been shown previously that Trp10 is
important for biological activity (41). Replacement of Trp10
with threonine resulted in a 30-fold decrease in activity,
whereas replacement with phenylalanine only reduced activity
3-fold suggesting that an aromatic residue is required at posi-
tion 10.Mutation of residues 9 and 11 in ImI had little effect on
activity at the7 subtype (41). The x-ray structure of ImI bound
to AChBP shows that Trp10 makes a number of contacts with
the complementary binding side of the receptor at sites that the
4/7 -conotoxin analogue [A10L,D14K]-PnIA does not (34).
Vc1.1 has a tyrosine in position 10, which has an aromatic char-
acter yet also a hydroxyl group. It may be this hydroxyl group
that is interfering with the interaction with the 7 receptor, or
it may be a result of the longer second loop causing a disruption
of the required interactions.
The structure-activity relationships of the 4/7 -conotoxin
MII have been studied in detail recently (42, 43). Interestingly,
bothMII andVc1.1 act on32 nAChR subtypes, but there are
some significant differences in their activity profiles. MII is
effective in the nanomolar range, has a greater selectivity for
32 thanVc1.1, but has a significantly lower potency for34
subtypes. MII also has a greater
potency for the 7 nAChR subtype,
whereas Vc1.1 has minimal effect
(44, 45). An alanine scan of MII
showed that the mutations N5A,
P6A, and H12A had a substantial
effect on potency at the 32 and
6 nAChR subtypes, whereas H9A
and L15A had more modest effects
for32 subtypes only (42, 43). Fur-
thermore, mutation of His9, Glu11,
and Leu15 to alanine has been
shown to increase the selectivity of
MII for6-containing nAChRs (43).
In addition to the highly conserved
proline at position 6, some of the
residues important for the activity
of MII are mirrored in the sequence
of Vc1.1. Both peptides have a neg-
atively charged residue at position 11, Asp in Vc1.1 and Glu in
MII, that may contribute to the selectivity of MII and Vc1.1 for
the 3 subunit. MII and Vc1.1 also both have a histidine at
position 12, and as the potency of MII was found to be pH-de-
pendent, it has been suggested that this histidine is charged in
the active form of the peptide (42).We have found that a reduc-
tion of pH increases the potency of Vc1.1, which supports the
proposal that a protonated histidine may be important for the
receptor interaction. Finally, the leucine at position 15 inMII is
replaced with isoleucine in Vc1.1, which would have a similar
hydrophobic interaction with the receptor. Therefore, the
combined structure and activity data suggest that it is the
N-terminal portion of Vc1.1 that is the major determinant of
binding to the nAChR, with residues in the C-terminal portion
of the molecule responsible for more subtle variations on
potency and selectivity.
To our knowledge, this is the first report on the selectivity of
Vc1.1 for nAChR subtypes. Vc1.1 had been assumed, based on
the previously reported chromaffin cell binding studies, to be
selective for 34-containing subtypes (6), and the involve-
ment of the 5 subunit with 34 nAChRs had been specu-
lated. We show that the potency of Vc1.1 was unchanged at
352 but exhibits a 5-fold reduction at 354 nAChRs
relative to 34. The homomeric 7 nAChR exhibits 20%
block in the presence of 30 M Vc1.1. We have demonstrated
that the post-translationally modified form of Vc1.1, vc1a,
which is found in the venom, does not inhibit ACh-evoked cur-
rents mediated by any of the nAChR subtypes expressed in
Xenopus oocytes. This is an interesting result from a biological
viewpoint, because it implies that the cone snail is investing
valuable metabolic energy into deactivating Vc1.1. However, it
seems more likely that vc1a is produced to target an as yet
unknown receptor target.
Finally, Vc1.1 has been reported to have an important con-
tribution to the potential role of nAChRs in pain perception (8),
because it is able to inhibit a vascular response to pain (6) and is
able to reduce chronic pain in several animal models of human
neuropathy (8, 9). Antagonists of nAChRs such as Vc1.1 might
reduce the increase in axonal excitability produced by neuronal
FIGURE 9. A comparison of the crystal structure of [A10L,D14K]-PnIA bound to AChBP (23) with the
structureofVc1.1.a, anoverlayof theVc1.1NMRensemble (blue)with thex-ray structureof [A10L,D14K]-PnIA
(red) bound to AChBP illustrating the similarity in side-chain conformations at positions 6 and 14. Disulfide bonds
are shown in yellow (Vc1.1) and green ([A10L,D14K]-PnIA). b, a ribbon representation of Vc1.1 (blue) within the
binding pocket of AChBP (principle side in purple and complementary side in yellow). The backbone of Vc1.1 has
beenoverlaidwith that of [A10L,D14K]-PnIA (not shown) to illustrate thepotential bindingmodeof Vc1.1. Pro6
of Vc1.1 (green) would potentially have hydrophobic interactions with Trp145 and Tyr53 (green) of the AChBP,
similar to those seen for [A10L,D14K]-PnIA. In contrast, Glu14 (pink) is solvent-exposed, and hence this residue
is less likely to be crucial for receptor interactions compared with Pro6.
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nAChR activation (9). The structure reported here should open
new opportunities for further development of Vc1.1 or ana-
logues as analgesic agents.
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